Article Versions Notes

Hou Z, Lin S, Du T, Wang M, Wang W, You S, Xue N, Liu Y, Ji M, Xu H, et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals. 2023; 16(5):749. https://doi.org/10.3390/ph16050749

Hou, Zhenyan, Songwen Lin, Tingting Du, Mingjin Wang, Weida Wang, Shen You, Nina Xue, Yichen Liu, Ming Ji, Heng Xu, and et al. 2023. "S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer" Pharmaceuticals 16, no. 5: 749. https://doi.org/10.3390/ph16050749

Hou, Z., Lin, S., Du, T., Wang, M., Wang, W., You, S., Xue, N., Liu, Y., Ji, M., Xu, H., & Chen, X. (2023). S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals, 16(5), 749. https://doi.org/10.3390/ph16050749